Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with < em > BRCA < /em > mutation and/or maintenance therapy

CONCLUSION: CRS may not be a prognostic factor in patients with BRCA mutations and those receiving frontline maintenance therapy.PMID:38551024 | DOI:10.3802/jgo.2024.35.e73

Source: Journal of Gynecologic Oncology - March 29, 2024 Category: OBGYN Authors: Young Joo Lee Yoon Kyung Shin Nae Ry Kim Se Ik Kim Yoo-Young Lee Jeong-Yeol Park Jae-Weon Kim Hyun-Woong Cho Jung-Yun Lee Source Type: research